Hualan Biologicals: A subsidiary company has received a notification letter for approval of drug clinical trials.

Hualan Biotechnology announced that its holding subsidiary Hualan Vaccine recently received a "Notice of Approval for Clinical Trial of Drugs" issued by the National Medical Products Administration. The drug is a recombinant herpes zoster vaccine, classified as a Class 1.3 biological product for prevention, and the application type is a new drug used for preventing herpes zoster. The drug meets the relevant requirements for drug registration, and it is recommended to conduct clinical trials for preventing herpes zoster.